首页> 外文OA文献 >CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease

【2h】

CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease

机译：CCL4介导的患有纳米颗粒的脾酪氨酸激酶（SYK）抑制剂的靶向靶向抑制剂可缓解炎性肠病疾病

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Wenbin Gong; Jiafei Yu; Tao Zheng; Peizhao Liu; Fan Zhao; Juanhan Liu; Zhiwu Hong; Huajian Ren; Guosheng Gu; Gefei Wang; Xiuwen Wu; Yun Zhao; Jianan Ren;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease [J] . Wenbin Gong, Jiafei Yu, Tao Zheng, Clinical and Translational Medicine . 2021,第2期

机译：CCL4介导的患有纳米颗粒的脾酪氨酸激酶（SYK）抑制剂的靶向靶向抑制剂可缓解炎性肠病疾病
2. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events [J] . ZengK.-W., WangS., DongX., Toxicology and Applied Pharmacology . 2014,第3期

机译：倍半萜二聚体（DSF-27）通过靶向脾酪氨酸激酶（Syk）和Janus激酶2（Jak2）抑制小胶质细胞神经炎介质的释放：参与炎症事件的两种主要非受体酪氨酸信号蛋白
3. Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases [J] . Biagioli Michele, Mencarelli Andrea, Carino Adriana, Inflammatory bowel diseases . 2018,第1期

机译：脾酪氨酸激酶（SYK）在炎症肠疾病中肠酪氨酸激酶（SYK）作用的遗传和药理解剖
4. Natural anti-Inflammatory Compounds for the Management and Adjuvant Therapy of Inflammatory Bowel Disease (IBD) and its Drug Delivery System(DDS) for Targeted to Colon. [C] . Annual meeting exposition of the Controlled Release Society . 2009

机译：用于炎症性肠病（IBD）的管理和佐剂治疗的天然抗炎化合物及其药物递送系统（DDS）用于靶向结肠。
5. Pharmacological Characterization of TAS05567, a Potent and Selective Inhibitor of Spleen Tyrosine Kinase, in Animal Models of Inflammatory Diseases and B-cell Malignancies [D] . 林宏明 2019

机译：TAS05567，脾酪氨酸激酶的强效和选择性抑制剂，在炎症性疾病和B细胞恶性动物模型中的药理特性
6. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor RO9021 impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy [O] . Cheng Liao, Jonathan Hsu, Yong Kim, 2013

机译：新型口服生物可利用的小分子抑制剂RO9021对脾酪氨酸激酶（SYK）的选择性抑制会影响多种先天和适应性免疫应答：SYK抑制剂在自身免疫性疾病治疗中的意义
7. Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases [O] . Michele Biagioli, Andrea Mencarelli, Adriana Carino, 2017

机译：脾酪氨酸激酶（SYK）在炎症性肠病肠炎症和免疫功能障碍中的作用遗传和药理解剖

CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease

著录项

引文网络

相似文献

相关主题

期刊订阅